DelMar Pharmaceuticals Inc (NASDAQ:DMPI) gapped down prior to trading on Wednesday . The stock had previously closed at $1.49, but opened at $1.57. DelMar Pharmaceuticals shares last traded at $0.91, with a volume of 138,414 shares changing hands.
Several equities analysts have recently weighed in on the company. ValuEngine downgraded DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Thursday, July 11th.
The company has a market capitalization of $4.46 million, a PE ratio of -0.17 and a beta of 0.85. The company’s fifty day moving average is $1.49.
A hedge fund recently raised its stake in DelMar Pharmaceuticals stock. Virtu Financial LLC lifted its stake in DelMar Pharmaceuticals Inc (NASDAQ:DMPI) by 99.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 98,554 shares of the company’s stock after purchasing an additional 49,200 shares during the quarter. Virtu Financial LLC owned about 0.39% of DelMar Pharmaceuticals worth $48,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.85% of the company’s stock.
About DelMar Pharmaceuticals (NASDAQ:DMPI)
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Article: What moving averages are used to define a golden cross?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.